To appraise the clinical and cost effectiveness of nivolumab within its marketing authorisation for adjuvant treatment of resected stage III and IV melanoma.
Status In progress
Process STA pre-2018
ID number 1316

Project Team

Project lead Thomas Feist

Email enquiries


Key events during the development of the guidance:

Date Update
16 August 2018 Committee meeting: 1
09 March 2018 Invitation to participate
05 January 2018 - 02 February 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
31 July 2017 In progress, DH referral received
09 March 2017 Invitation to partipate

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance